VEGFA and nonpapillary renal cell carcinoma: However, the phase II randomized control study among 49 patients with VEGF-refractory metastatic ccRCC showed that AZD-2014 was less toxic but also less effective than everolimus in improving patients’ overall survival and preventing tumor progression (Powles et al., 2016).